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OBJECTIVES We sought to investigate whether abciximab, tirofiban and eptifibatide achieve comparable
antiplatelet effects with coronary stenting.
BACKGROUND The glycoprotein (GP) IIb/IIIa antagonists abciximab, tirofiban and eptifibatide differ in
chemical structure, binding site and pharmacokinetics.
METHODS Sixty patients undergoing coronary stenting were randomly assigned to abciximab (bolus
0.25 mg/kg body weight, infusion 10 mg per min for 12 h), tirofiban (bolus 10 mg/kg, infusion
0.15 mg/kg per min for 72 h) or eptifibatide (bolus 180 mg/kg, infusion 2 mg/kg per min for
72 h). We took serial blood samples to analyze platelet function by using flow cytometry,
turbidimetric aggregometry and the rapid platelet-function assay (RPFA).
RESULTS As assessed by RPFA, platelet aggregation after 2 h of infusion was reduced to 5.9 6 7.8%
(mean 6 SD) of baseline by abciximab, to 5.0 6 5.4% by tirofiban and to 7.8 6 7.1% by
eptifibatide (p 5 0.42). Turbidimetric aggregometry with adenosine diphosphate stimulation
yielded similar results, whereas percent inhibition of platelet aggregation after thrombin
receptor stimulation was 45.8 6 16.8% with abciximab, 51.3 6 17.6% with tirofiban and
52.9 6 14.8% with eptifibatide (p 5 0.37). Tirofiban and eptifibatide maintained their level
of platelet inhibition during infusion. Flow cytometry revealed that the reduction in the
monocyte-platelet interaction by abciximab, tirofiban and eptifibatide was not significantly
different (20.0 6 21.9%, 23.8 6 18.2% and 21.0 6 19.8%, respectively; p 5 0.87).
CONCLUSIONS Abciximab, tirofiban and eptifibatide, at currently recommended doses, achieved similar levels
of inhibition of platelet aggregation and a similar reduction in the platelet–monocyte
interaction. (J Am Coll Cardiol 2001;37:1323–8) © 2001 by the American College of
Cardiology
Glycoprotein (GP) IIb/IIIa blockade reduces the risk of
percutaneous coronary interventions substantially (1,2). In
many countries, the GP IIb/IIIa antagonists—abciximab,
tirofiban and eptifibatide—have been approved for clinical
use on the basis of several phase III trials. Among these
trials, however, the risk reduction by GP IIb/IIIa blockade
varies (1).
Abciximab, tirofiban and eptifibatide differ in chemical
structure, binding site and pharmacokinetics (3). Abciximab
is the humanized chimeric Fab fragment of a monoclonal
mouse antibody (3–5). Abciximab cross reacts with the avb3
integrin on endothelial cells and smooth muscle cells and
with the aMb2 integrin (Mac-1) on myeloid leukocytes
(6,7). Platelet-bound abciximab persists for many days (5).
Tirofiban is a nonpeptide tyrosine derivative that blocks
arginine-glycine-aspartic binding sites of GP IIb/IIIa (8).
The cyclic heptapeptide eptifibatide blocks the lysine-
glycine-aspartic binding site (9). Tirofiban and eptifibatide
are competitive inhibitors with short half-lives. Continuous
infusion is needed for sustained platelet inhibition (3,8,9).
The clinical relevance of the pharmacologic differences
between abciximab, tirofiban and eptifibatide is currently
unclear. Thus far, there are only limited data on the
differential efficacy of the three agents in the peri-
interventional inhibition of platelet aggregation (10). More-
over, other platelet effects of abciximab, such as inhibition of
the platelet-monocyte aggregation (11) or induction of
alpha-degranulation, are not very well characterized for
tirofiban and eptifibatide (12,13). Therefore, we performed
a prospective, randomized study comparing the platelet
effects of abciximab, tirofiban and eptifibatide in patients
undergoing stent implantation.
METHODS
Patient selection and study protocol. The study group
consisted of patients undergoing intracoronary stent place-
ment for symptomatic coronary artery disease. Exclusion
criteria included contraindications for aspirin, ticlopidine or
GP IIb/IIIa blockade, absolute indication for anticoagula-
tion, acute myocardial infarction, serum creatinine concen-
tration $2.0 mg/dl and .24 h of antecedent treatment with
ticlopidine. All patients gave written, informed consent.
The study was approved by our institutional Ethics Com-
mittee.
Immediately before the balloon angioplasty that preceded
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stenting, the patients were assigned to one of three open-
label treatment regimens by means of a computer-generated
randomization scheme: 1) abciximab bolus of 0.25 mg/kg
body weight, followed by a continuous infusion at
10 mg/min for 12 h (14); 2) tirofiban bolus of 10 mg/kg,
followed by a continuous infusion at 0.15 mg/kg per min for
72 h (15); and 3) eptifibatide bolus of 180 mg/kg, followed
by a continuous infusion at 2 mg/kg per min for 72 h (16).
The concomitant preinterventional heparin dosage was
70 U/kg in the abciximab group and 100 U/kg in the other
groups. In addition, all patients received ticlopidine and
aspirin (100 mg twice daily), starting 1 to 8 h before the
intervention. Ticlopidine was administered twice daily at
500 mg for the first three doses, and subsequently at 250 mg
for four weeks. We performed stent placement, as described
previously (17).
Peripheral venous blood samples were taken before the
start of drug administration, as well as 2, 24, 48, 72 and 96 h
after the start of infusion. In patients randomized to
tirofiban or eptifibatide, we obtained an additional sample at
2 h after discontinuation of the infusion. We collected 2.5
ml of blood in tubes with disodium ethylene diamine
tetra-acetic acid for determination of platelet count by use of
a Coulter Counter (Beckman Coulter, Krefeld, Germany).
For flow cytometry, 1 ml of blood was collected into tubes
with a fixative solution (1:3 vol/vol) containing metacroleine
(Cyfix II, gift of Dr. Andreas Ruf, Karlsruhe, Germany), as
described previously (11,13). For analysis of platelet aggre-
gation, 15 ml of blood was collected in citrate tubes (3.8%)
for studies on abciximab or tirofiban, or in hirudin tubes
(500 mg/liter) for studies on eptifibatide (18). In prelimi-
nary studies, we compared hirudin with citrate as an
anticoagulant for platelet function tests. These studies did
not show appreciable differences in any of the platelet
function tests after administration of abciximab or tirofiban.
Platelet aggregometry. For analysis of thrombin receptor-
induced platelet aggregation in whole blood, we used the
rapid platelet-function assay (RPFA, Accumetrics, San
Diego, California). The details of this rapid, automated,
point-of-care platelet-function test have been described
previously (19,20). Briefly, the RPFA, assesses the interac-
tion between platelet GP IIb/IIIa receptors and fibrinogen-
coated beads after stimulation with the thrombin receptor-
activating peptide (TRAP) ([iso-TRAP]) ([iso-S]FLLRN)
at 4 mmol/liter, which corresponds to a 5-mmol/liter dose of
TRAP (SFLLRNPNDKYEPF). The rate of aggregation is
calculated automatically and expressed as platelet aggrega-
tion units. We report RPFA data as percentages of the
baseline value before administration of the study drug.
In addition, we analyzed platelet aggregation in platelet-
rich plasma by turbidimetric aggregometry by using a
two-channel Chronolog aggregometer (Nobis, Germany)
(13). Platelet-rich plasma was prepared by centrifugation at
200g for 20 min. After adjustment from baseline, 20
mmol/liter of adenosine diphosphate (ADP; Sigma, Stein-
heim, Germany) or 50 mmol/liter of TRAP (Sigma) was
added, and aggregation was recorded for 5 min. We assessed
the maximal initial slope of the increase in photovoltage as
a measure of the rate of aggregation. The results are
expressed as percentages of the baseline value before admin-
istration of the study drug.
Flow cytometry. Immunostaining and flow cytometry were
performed without ex vivo addition of platelet agonists, as
described previously (11,13). We stained leukocytes in
whole blood by triple-color immunofluorescence with the
use of fluorescein isothiocyanate (FITC)-labeled monoclo-
nal antibodies (mAbs) for the aM chain of Mac-1 (CD11b);
phycoerythrin (PE)-labeled mAbs for GP Iba of the von
Willebrand factor receptor complex (CD42b); and PE-
Cy5-labeled mAbs for the monocyte marker CD14 (endo-
toxin receptor; all mAbs from Immunotech, Hamburg,
Germany). As shown earlier, binding of the anti-CD11b
mAbs used in our study was not affected by administration
of abciximab (11). Platelets were stained with PE-labeled
CD42b mAbs and FITC-conjugated mAbs for P-selectin
(CD62P, Dianova, Hamburg, Germany). Nonspecific
membrane immunofluorescence is determined by use of an
irrelevant isotype-matched fluorescein-conjugated immuno-
globulin G (Dianova). We used a fluorescence activated cell
sorter scan (Becton-Dickinson, Heidelberg, Germany)
equipped with a 488-nm argon laser at 500 mW, and we
analyzed 5,000 events. We identified monocytes as anti-
CD14-positive events on the histogram generated by PE-
Cy5 fluorescence, and platelets by size and CD42b immu-
nofluorescence. The mean channel of fluorescence intensity
was taken as a measure for antibody binding, and thus
antigen surface exposure.
Statistical analysis. The primary end point was the inhi-
bition of platelet aggregation, as assessed by RPFA after 2 h
of infusion. We considered abciximab as the reference drug,
because abciximab was the only drug with documented
clinical efficacy in the setting of stenting (14). We intended
an 80% power to detect a 10% difference in inhibition of
platelet aggregation between abciximab and one of the two
other agents, with a level of significance (p value) ,0.05.
On the basis of earlier studies, we assumed a standard
deviation of 10% for variables of platelet aggregation (13).
Thus, we obtained a sample size of 20 patients in each
group.
Discrete variables, expressed as counts, were tested by
using the Fisher exact test. The results of continuous
variables were reported as the mean value 6 SD, and were
Abbreviations and Acronyms
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FITC 5 fluorescein isothiocyanate
GP 5 glycoprotein
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tested by analysis of variance, followed by the Scheffe´ test,
where appropriate. To account for potential deviations from
normal distribution, we corroborated these analyses by
nonparametric testing using the Kruskal-Wallis test, fol-
lowed by the Mann-Whitney U test, where appropriate.
Unless stated otherwise, the results of the nonparametric
tests confirmed those of the parametric tests. A p value
,0.05 (two-tailed test) was regarded as significant.
RESULTS
Study cohort, platelet counts and clinical events. The
study groups were not significantly different with respect to
major demographic, angiographic and procedural variables
(Table 1). In all patients, stenting achieved residual stenosis
,15%, with Thrombolysis In Myocardial Infarction
(TIMI) flow grade 3. Platelet counts at baseline (Table 1)
and during follow-up were not significantly different be-
tween the three groups, and we did not find a significant
decrease in the average platelet count after the intervention
in any of the groups. Nevertheless, in one patient assigned
to abciximab, the platelet count dropped to 16 103/ml at
24 h after infusion (confirmed with a citrated sample);
otherwise, thrombocytopenia #50 103/ml was not encoun-
tered in any of the patients. Access site complications
requiring surgical intervention, or serious bleeding compli-
cations, such as hemorrhagic stroke, gastrointestinal or
other bleeding necessitating transfusion, did not occur in
either group. During 30-day follow-up, none of the patients
incurred a serious adverse cardiac event, including death,
large myocardial infarction (Q-wave or creatinine kinase .5
times the upper limit) or target vessel repeat intervention.
Inhibition of platelet aggregation. As assessed by RPFA
(Fig. 1), all agents achieved a mean inhibition of platelet
aggregation .80% during infusion. This mean level of
inhibition was maintained during infusion of tirofiban and
eptifibatide. After discontinuation of infusion, recovery of
platelet aggregation was delayed with abciximab and more
rapid with tirofiban and eptifibatide (Fig. 1). With abcix-
imab and tirofiban or eptifibatide, there were no significant
differences in either mean platelet inhibition or the percent-
age of patients achieving .80% inhibition at 2 h (Fig. 2).
The time courses of the mean rate of ADP-induced
platelet aggregation (Fig. 3), as assessed by turbidimetric
aggregometry, were largely similar to those of RPFA. When
comparing the effects of abciximab at 2 h with those of
tirofiban or eptifibatide (Fig. 2), we did not find significant
differences in the mean inhibition or the percentage of
patients achieving .80% inhibition of the ADP-induced
aggregation rate. With all three agents, inhibition of
TRAP-induced platelet aggregation was substantially less
Table 1. Baseline Demographic, Clinical and Angiographic Characteristics of the Study Group
Abciximab Group
(n 5 20)
Tirofiban Group
(n 5 20)
Eptifibatide Group
(n 5 20)
p
Value
Age (yr) 67 6 10 64 6 12 65 6 12 0.77
Women 4 3 2 0.68
Platelet count (1/ml) 253 6 89 235 6 77 242 6 64 0.77
Active smoker 8 8 9 0.93
Hypercholesterolemia 15 18 15 0.40
Hypertension 15 16 13 0.55
Diabetes 6 4 3 0.50
Unstable angina 7 6 8 0.80
Multivessel disease 17 16 18 0.73
Reduced LV function 6 7 9 0.61
Complex lesions 17 18 16 0.68
Chronic occlusions 2 3 4 0.94
Lesion in venous graft 2 2 2 1.00
Vessel size (mm) 3.06 6 0.58 3.21 6 0.70 3.19 6 0.56 0.69
Stenosis before stenting (%) 77.4 6 9.8 74.2 6 16.2 73.6 6 15.6 0.66
Balloon/vessel ratio 1.11 6 0.12 1.10 6 0.13 1.10 6 0.12 0.62
Inflation pressure (atm) 13.6 6 2.3 13.8 6 2.7 13.3 6 2.5 0.85
Stented length (mm) 23.0 6 8.1 21.3 6 9.7 21.8 6 6.2 0.86
Stenosis after stenting (%) 3.1 6 11.1 4.4 6 10.4 5.9 6 8.8 0.69
Data are presented as the absolute number of patients or mean value 6 SD.
LV 5 left ventricular.
Figure 1. Time course of the rate of platelet aggregation after stimulation
with 4 mmol/liter of iso-TRAP, as assessed by RPFA during and after
infusion of abciximab for 12 h (solid circles), tirofiban for 72 h (solid
diamonds) or eptifibatide for 72 h (solid triangles). The plot shows the
mean value 6 SD. From 24 h onwards, the differences between the three
agents were statistically significant (p , 0.001).
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than inhibition of ADP-induced platelet aggregation (Fig.
4). At 2 h, the rate of TRAP-induced platelet aggregation
was inhibited by only ;50% on average, but there were no
significant differences between the three agents (p 5 0.37).
Inhibition of the platelet-monocyte interaction and
P-selectin exposure. With all three agents, GP Iba fluo-
rescence of the monocyte population decreased significantly
(p , 0.005) after 2 h and 24 h of infusion (Fig. 5, left
panel). This decrease was caused by a reduction in GP Iba
fluorescence intensity of the GP Iba-positive monocytes,
whereas the percentage of GP Iba-positive monocytes
remained essentially constant (data not shown). Among the
three agents, there were no significant differences in the
reduction of GP Iba fluorescence on monocytes (Table 2).
The reduction in the platelet-monocyte interaction by GP
IIb/IIIa antagonists was associated with a reduction in
surface expression of Mac-1 on GP Iba-positive monocytes
(Fig. 5, right panel). Again, this effect was not significantly
different between the three agents (Table 2).
With all three agents, we found a significant (p , 0.041)
increase in the percentage of P-selectin-positive platelets,
maximal at 2 h. This increase in P-selectin-positive platelets
did not show any significant differences between the three
agents (Table 2).
DISCUSSION
Our prospective, randomized trial investigated the platelet
effects of three approved GP IIb/IIIa antagonists at cur-
rently recommended dosages in the setting of coronary
stenting. Our major findings are: among abciximab, tirofi-
ban and eptifibatide, there are no significant differences in:
1) the mean inhibition of the rate of platelet aggregation
induced by ADP or thrombin-receptor stimulation at 2 h of
infusion; 2) the mean inhibition of platelet-monocyte inter-
actions; and 3) mean alpha-degranulation, as a measure of
antagonist-induced platelet activation.
Platelet aggregation. As in previous studies, analysis of
whole blood after low dose thrombin receptor stimulation
by the automated RPFA yielded results similar to those of
analysis of platelet-rich plasma after stimulation with high
Figure 2. Scatter plot of the rate of platelet aggregation after a 2-h infusion
of abciximab (solid circles), tirofiban (solid diamonds) or eptifibatide
(solid triangles), as assessed by rapid platelet-function assay (RPFA) with
4 mmol/liter of iso-thrombin receptor activating peptide or by turbidimet-
ric aggregometry with 20 mmol/liter of adenosine diphosphate. The p
values were calculated by one-way analysis of variance.
Figure 3. Time course of the rate of platelet aggregation after stimulation
with 20 mmol/liter of adenosine diphosphate, as assessed by turbidimetric
aggregometry during and after infusion of abciximab for 12 h (solid
circles), tirofiban for 72 h (solid diamonds) or eptifibatide for 72 h (solid
triangles). The plot shows the mean value 6 SD. From 24 h onwards, the
differences between the three agents were statistically significant (p ,
0.034).
Figure 4. Time course of the rate of platelet aggregation after stimulation
with 50 mmol/liter of thrombin receptor activating peptide, as assessed by
turbidimetric aggregometry during and after infusion of abciximab for 12 h
(solid circles), tirofiban for 72 h (solid diamonds) or eptifibatide for 72 h
(solid triangles). The plot shows the mean value 6 SD. At 24, 48 and
72 h, the differences between the three agents were statistically significant
(p , 0.002).
Figure 5. Time course of glycoprotein (GP) Iba immunofluorescence of
monocytes as a measure of platelet-monocyte binding (left panel), and
Mac-1 immunofluorescence of GP Iba-positive monocytes as a measure of
Mac-1 expression on monocytes with adherent platelets (right panel)
before and during infusion of abciximab (solid circles), tirofiban (solid
diamonds) or eptifibatide (solid triangles). The plot shows the mean
value 6 SD.
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dose ADP by turbidimetric aggregometry (20,21). Both
methods consistently showed a mean inhibition of platelet
aggregation .90% at 2 h, with no significant differences
between the three agents. With stimulation by high dose
TRAP, the mean inhibition of platelet aggregation by the
three agents was substantially weaker, albeit not significantly
different among them. In an earlier study (22), abciximab
inhibited thrombin-induced platelet aggregation only by
;50%, despite ;80% inhibition of ADP-induced platelet
aggregation. This discrepancy can be explained by mobili-
zation of nonblocked GP IIb/IIIa receptors by the most
potent platelet stimulus thrombin (22,23). Our study dem-
onstrates that this mechanism affects the antiplatelet efficacy
of tirofiban and eptifibatide to a similar extent.
Although the optimal level of platelet inhibition at
various time points has not been definitely established
(24–27), it is commonly accepted that .80% inhibition of
ADP-induced platelet aggregation is needed for effective
prevention of thrombotic events after coronary interven-
tions. We therefore analyzed those patients achieving this
level of inhibition, and again, we found no significant
differences between the three agents. It has to be noted,
however, that while most patients achieved .80% inhibi-
tion, 8.3% did not by RPFA and 10% did not by turbidi-
metric aggregometry. Hence, there is still room for im-
proved dosing approaches, such as the double bolus regimen
recently pursued in the Enhanced Suppression of the
Platelet IIb/IIIa Receptor with Integrilin Therapy (ESPRIT)
trial (28).
Platelet-monocyte interaction. We addressed heterotypic
adhesion of platelets to leukocytes, which appears to play a
role in the regulation of inflammatory responses in ischemic
heart disease (11,29,30). Recently, we showed that abcix-
imab reduced the mass of platelets attached to circulating
myeloid leukocytes in patients with acute myocardial infarc-
tion (11). The reduction in the platelet-monocyte interac-
tion by abciximab was associated with downregulation of
surface expression of Mac-1, one of the major leukocyte
adhesion molecules (11). Xiao et al. (31) described a
reduction of the platelet-neutrophil interaction by tirofiban,
but they did not address the consequential changes in
Mac-1 expression. In this study, we show that inhibition of
the platelet-monocyte interaction by abciximab, tirofiban
and eptifibatide is similar and leads to a comparable down-
regulation of Mac-1 in circulating platelet-leukocyte aggre-
gates.
Agonist-induced platelet activation. We found a compa-
rable increase in P-selectin surface expression after abcix-
imab, tirofiban and eptifibatide. Engagement of the GP
IIb/IIIa receptor by natural ligands or antagonists induces
platelet activation (12,32,33). Recently, we were able to
demonstrate antagonist-induced platelet activation in pa-
tients treated with abciximab, by showing an abciximab-
induced increased P-selectin surface expression (13). By
demonstrating a similar increase in P-selectin surface ex-
pression with all three agents, our current study does not
suggest that there are major differences in antagonist-
induced platelet activation in the clinical setting.
Study limitations. Our study was not powered to specifi-
cally address the proportions of patients reaching a certain
level of platelet inhibition. Nevertheless, the distribution of
data points (Fig. 2) does not suggest major differences.
We intended to analyze the three GP IIb/IIIa inhibitors
at currently recommended dosages, as well as concomitant
medications. Therefore, heparin dosing differed between the
three treatment arms. We cannot fully exclude that this
might have had an effect on our platelet function studies.
Heparin can directly activate platelets, and yet may limit
thrombin-induced platelet activation.
Our study focused on platelet effects. Contrary to tirofi-
ban and eptifibatide, abciximab has nonplatelet effects, such
as inhibition of the vitronectin receptor and Mac-1. In this
respect, it is noteworthy that with abciximab, but not with
the other agents, downregulation of the number of surface-
expressed Mac-1 complexes in platelet-leukocytes aggre-
gates is complemented by direct Mac-1 blockade (6). Such
nonplatelet effects were not addressed in our study (6,7).
Implications. By demonstrating comparable platelet effects
of various GP IIb/IIIa inhibitors, the data reported here
yielded a rationale for trials that directly compare the clinical
efficacy of various GP IIb/IIIa inhibitors, such as TARGET
(do Tirofiban And ReoPro Give similar Efficacy outcomes
Trial) (34). In the meantime, the 30-day primary end point
analysis of TARGET was reported. It showed a signifi-
cantly better outcome with abciximab than with tirofiban.
Among potential explanations for the superiority of abcix-
imab in TARGET, our study points toward the Mac-1 and
vitronectin receptor-dependent nonplatelet effects, and it
Table 2. Relative Changes in Platelet-Monocyte Interaction, Mac-1 Expression on Monocytes
With Adherent Platelets and P-Selectin Surface Expression on Platelets
Abciximab Tirofiban Eptifibatide p Value
DGP Iba fluorescence
on monocytes
220.0%
(27.9% to 232.2%)
223.8%
(213.7% to 233.9%)
221.0%
(210.0% to 232.0%)
0.87
DMac-1 fluorescence on
GP Iba-positive monocytes
227.1%
(212.3% to 242.0%)
224.7%
(29.5% to 240.0%)
223.7%
(29.8% to 237.6%)
0.93
DP-selectin-positive
platelets
53.6%
(6.1% to 101.2%)
44.0%
(9.3% to 78.7%)
67.20%
(17.5% to 117.1%)
0.76
Data are presented as the mean value (95% confidence interval). Confidence intervals that do not include 0 indicate significant
changes at p , 0.05.
GP 5 glycoprotein.
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refutes failure of platelet inhibition during the steady state
of infusion at 2 h and beyond.
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